First successful treatment of Nocardia farcinica brain abscess with moxifloxacin.
Nocardia farcinica is an emerging pathogen in immunosuppressed patients causing both localized and disseminated infections. Many strains of this species are multidrug-resistant and require long-term antibiotic therapy, and consequently the choice of an oral treatment can be problematic. We report here the first case of successful treatment of N. farcinica brain abscess in a renal transplant recipient with an extended-spectrum fluoroquinolone, moxifloxacin.
Fihman
Vincent
V
Faculté de Médecine Lariboisière-Saint Louis, Université Paris 7, Paris, France. vincent.fihman@lrb.aphp.fr
Berçot
Béatrice
B
Mateo
Joaquim
J
Losser
Marie-Reine
MR
Raskine
Laurent
L
Riahi
Jacques
J
Loirat
Philippe
P
Pors
Marie-José Sanson-Le
MJ
D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D001707:Biopsy, Needle; D001922:Brain Abscess / Q000188:drug therapy*; D024841:Fluoroquinolones; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016030:Kidney Transplantation / Q000276:immunology*; D008169:Lung Abscess / Q000473:pathology; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D000077266:Moxifloxacin; D009615:Nocardia / Q000302:isolation & purification; D009617:Nocardia Infections / Q000188:drug therapy*; D011804:Quinolines / Q000627:therapeutic use*; D012336:RNA, Ribosomal, 16S / Q000235:genetics; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D007166:Immunosuppressive Agents; D011804:Quinolines; D012336:RNA, Ribosomal, 16S; D000077266:Moxifloxacin